Abstract

Repligen will report first‑quarter 2026 results on May 5, 2026, Pre‑Market, and this preview frames consensus expectations for revenue, margins and adjusted EPS while examining product‑line drivers, operating dynamics into the print, and the prevailing institutional stance ahead of the release.

Market Forecast

Based on the latest projections, Repligen’s first‑quarter 2026 revenue is estimated at 192.28 million US dollars, implying approximately 17.36% year‑over‑year growth, with adjusted EPS forecast at 0.39, up about 11.81% year over year; current models also point to EBIT of 21.55 million US dollars, up roughly 19.06% year over year. Forecasts for gross margin and net margin specific to the quarter were not disclosed, so the focus remains on the expected mid‑teens revenue growth and double‑digit EPS trajectory. Repligen’s core Products line remains the principal engine, supported by continued portfolio adoption and commercial enablement; the company’s recent expansion of its Training & Innovation network is designed to support pre‑ and post‑sale engagement and deepen utilization across customers. Within Products, chromatography and filtration solutions are positioned as the most promising drivers; the Products line delivered 197.73 million US dollars last quarter and, given its contribution to over 99% of sales, this portfolio effectively underpinned the company’s 18.12% year‑over‑year revenue increase and is expected to grow broadly in line with the 17.36% company revenue forecast in the current quarter.

Last Quarter Review

In the prior quarter, Repligen reported revenue of 197.91 million US dollars, up 18.12% year over year, with a gross profit margin of 52.46%, GAAP net income attributable to the company of 13.29 million US dollars, a net margin of 6.71%, and adjusted EPS of 0.49 (up 11.36% year over year); quarter‑over‑quarter net income contracted by 10.89%, reflecting sequential normalization after a stronger finish to the prior period. A notable highlight was broad‑based outperformance versus expectations: revenue exceeded projections by 5.01 million US dollars and adjusted EPS surpassed by 0.05, reflecting disciplined cost control and favorable mix against a conservative baseline. On the business mix, Products generated 197.73 million US dollars, accounting for approximately 99.91% of total sales, with “royalties and other” contributing a minimal 0.19 million US dollars; Products thus drove the 18.12% year‑over‑year step‑up and framed a solid starting point for early‑2026 demand.

Current Quarter Outlook

Products portfolio: sustaining growth and mix quality into Q1 2026

The Products portfolio remains the centerpiece of Repligen’s near‑term performance, and consensus modeling for 192.28 million US dollars of Q1 revenue assumes momentum in its core offerings and continued breadth across accounts. Last quarter’s 52.46% gross margin serves as a relevant baseline for assessing near‑term conversion, with mix a key determinant: higher consumable pull‑through and favorable price‑mix can support contribution even without large step‑ups in volumes. Operating expense discipline and incremental productivity from scaled commercial programs should also help translate revenue gains into EBIT and EPS leverage, consistent with forecasts calling for approximately 19.06% EBIT growth and 11.81% EPS growth year over year. Seasonally, Repligen’s March quarter does not always capture the full benefit of back‑half customer budgets; the current outlook embeds steady orders and execution without requiring atypical linearity. The Products line’s ability to maintain healthy book‑to‑bill through routine engagements and training‑led adoption is central to management’s execution case into the print. While sequential net income softened in the prior quarter, the year‑over‑year trajectory and beat‑to‑consensus profile set a constructive base for Q1, assuming stable input costs and no adverse pricing developments.

Most promising growth driver: chromatography and filtration within Products

Chromatography and filtration solutions within Products are set up as the most promising demand vector for Q1 2026, supported by expanded customer enablement through the Training & Innovation Center network and deepening cross‑selling across installed accounts. These offerings benefit from recurring utilization, embedded in workflows that can both expand with new programs and intensify with higher run‑rates; that dynamic tends to sustain revenue visibility in the mid‑teens growth range, aligning with the 17.36% company‑level forecast. The prior quarter’s 197.73 million US dollars in Products revenue underscores the scale from which these sub‑portfolios operate, and the current sequence suggests the combination of new customer additions and broader deployment within existing sites can lift volume without disproportionate cost. Analysts emphasizing “innovation and cross‑selling momentum” anticipate that continued platform penetration and attach rates should support a stable gross margin mix in the nearer term. The commercial emphasis on pre‑ and post‑sale support also improves conversion cycles, as customers can validate configurations and rapidly deploy, which is consistent with management’s focus on operational throughput. Overall, chromatography and filtration are well located within the broader Products structure to maintain or exceed the company’s year‑over‑year revenue cadence this quarter.

Key stock price swing factors this quarter: delivery linearity, mix, and execution against expectations

Repligen’s share performance around the print is likely to be most sensitive to delivery linearity, mix quality and how results compare with the current consensus posture of mid‑teens revenue and double‑digit EPS growth. A print in line with revenue at approximately 192.28 million US dollars, paired with a stable gross margin and clear progress on operating leverage, would validate the EBIT and EPS trajectories and likely keep sentiment constructive. Conversely, any unexpected skew toward lower‑margin configurations or elongated conversion cycles could weigh on perceived throughput and near‑term margin expansion, even if full‑year targets remain intact. Investors will also parse book‑to‑bill commentary and qualitative demand color for early indications of second‑quarter cadence and whether recent commercial investments are translating into durable order momentum. Given the prior quarter’s beats on both revenue and EPS, the market has a clear baseline; sustaining that pattern would reinforce the majority bullish stance, while any softness in unit volumes or caution in customer ordering could introduce volatility. Finally, clarity around expense pacing and incremental productivity from the expanded customer training infrastructure will be important for interpreting the operating margin bridge from revenue to EBIT and EPS in the quarter.

Analyst Opinions

The skew of recent institutional commentary is decisively bullish, with a clear majority of Buy‑leaning views and no meaningful bearish calls in the latest window; based on the collected notes, the ratio is approximately 6 bullish to 0 bearish, reflecting confidence in continued execution, innovation cadence and cross‑selling leverage. H.C. Wainwright reiterated a Buy and a 208 US dollars price target, citing strong execution, innovation and cross‑selling momentum as pillars of sustained growth. Stifel maintained a Buy with a 207 US dollars target, emphasizing operational delivery and the portfolio’s ability to compound through customer expansion and attach rates. Barclays kept a Buy and a 175 US dollars target, signaling comfort with the near‑term growth and margin profile. UBS reiterated a Buy while adjusting its target to 195 US dollars, and Redburn (Rothschild & Co) initiated with Buy at 160 US dollars, underscoring the favorable setup into 2026. A separate Buy reaffirmation from another major broker reinforces the breadth of positive sentiment heading into the print. The majority view coalesces around several common themes. First, the Products line’s scale and breadth across workflows create multiple levers for growth without relying on a single product cycle; the mid‑teens revenue framework in the current quarter and the double‑digit EPS trajectory are considered achievable under normalized demand assumptions. Second, analysts point to ongoing innovation and commercial enablement—such as the expansion of training and customer support infrastructure—as mechanisms to shorten time‑to‑adoption and raise throughput, which supports both revenue conversion and gross margin resilience. Third, cross‑selling into the installed base remains a structural driver: once a core solution is placed, ancillary modules, configurations and consumables can be adopted alongside, providing incremental lift with limited incremental selling expense, a dynamic that is embedded in the EBIT growth forecasts of roughly 19.06% year over year. From a numbers perspective into Q1 2026, the majority of analysts anticipate revenue around 192.28 million US dollars and adjusted EPS near 0.39, with upside potential tied to mix and higher‑than‑modeled consumables pull‑through. The market will pay close attention to the quality of growth: if a larger portion of revenue comes from higher‑margin configurations and recurring consumables, it would reinforce confidence in sustained gross margin around recent levels. Conversely, if growth skews toward lower‑margin components, the focus would shift to scale benefits and cost controls to maintain the EBIT bridge implied by forecasts. Nevertheless, the consensus Buy stance reflects conviction that the portfolio’s breadth, innovation cadence and customer engagement investments are sufficient to deliver a Q1 performance that aligns with the mid‑teens revenue and double‑digit EPS blueprint. Looking beyond the print window, bullish analysts highlight that the company’s guidance cadence and communication have been prudent. In the most recent quarter, Repligen outperformed on both revenue and EPS relative to expectations, and the quarter‑over‑quarter net income dip occurred alongside healthy year‑over‑year expansion, a pattern that does not undermine the underlying demand trend. The willingness to invest in customer training and pre‑/post‑sale support is seen as complementary to the sales model, potentially raising conversion rates and shortening validation cycles, which should translate into steadier quarterly linearity. Street targets spanning 160 to 208 US dollars cluster around a constructive medium‑term outlook that assumes balanced growth and disciplined execution. With no prominent bearish calls in the tracked period and multiple Buy reiterations or initiations, the center of gravity remains positive heading into May 5, 2026. Ultimately, the majority view expects Repligen to deliver a quarter that validates the forecast profile—about 17.36% year‑over‑year revenue growth, approximately 19.06% EBIT growth and roughly 11.81% EPS growth—while demonstrating continued progress on product adoption, cross‑selling, and operational throughput.